Abbott Laboratories vs Johnson & Johnson

Full side-by-side comparison — 2026

Data as of May 20, 2026 · Updated automatically

10
ABT Wins
0
Tie
9
JNJ Wins

ABT

Price USD 87.31
P/E Ratio 23.7x
Div Yield 0.0289%
Beta 0.65
Sector Health Care

JNJ

Price USD 230.48
P/E Ratio 26.2x
Div Yield 0.0229%
Beta 0.26
Sector Health Care

Price Overview

Metric ABT JNJ
Current Price 87.31 230.48
Previous Close 88.38 229.32

Valuation

Metric ABT JNJ
Trailing P/E 23.66 26.24
Forward P/E 13.93 17.84
Price / Book 2.83 6.72
Price / Sales 3.26 5.66
EV / EBITDA 14.87 16.86

Dividends & Income

Metric ABT JNJ
Dividend Yield 0.0289% 0.0229%
Dividend Rate (Annual) 2.44 5.20
5-Year Avg Yield 1.67% 2.77%
Payout Ratio 0.6673% 0.5952%

Risk & Financial Health

Metric ABT JNJ
Beta (Volatility) 0.65 0.26
Debt / Equity 64.77 67.73
Quick Ratio 0.84 0.69
Current Ratio 1.39 1.03

Growth & Profitability

Metric ABT JNJ
Revenue Growth 0.0780% 0.0990%
Earnings Growth -0.1970% -0.5290%
Return on Equity 0.1233% 0.2642%
Revenue / Share 25.91 40.02
Trailing EPS 3.57 8.64
Forward EPS 6.06 12.71

Analyst Targets

Metric ABT JNJ
Analyst Mean Target 118.64 252.96
Analyst High Target 143.00 285.00
Analyst Low Target 92.00 155.00

Bottom Line: ABT vs JNJ

Abbott Laboratories (ABT) leads on 10 of 19 comparable metrics.

Abbott Laboratories is the stronger pick for value investors, while Johnson & Johnson may appeal to income investors.

Abbott Laboratories has a higher Earnings Growth (-19.70% vs -52.90%), which indicates profits are growing more quickly
Johnson & Johnson has a lower Beta (Volatility) (0.26 vs 0.65), which typically indicates less price volatility
Johnson & Johnson has a higher Trailing EPS (8.64 vs 3.57), which means higher earnings per share over the last 12 months

This comparison is based on publicly available financial data and is for informational purposes only. It is not investment advice. Past performance does not guarantee future results.

ABT Abbott Laboratories

Best for Value Investors
• Lower Trailing P/E: 23.66
• Lower Forward P/E: 13.93
• Lower Price / Book: 2.83
Best for Conservative Investors
• Lower Debt / Equity: 64.77
• Higher Quick Ratio: 0.84
• Higher Current Ratio: 1.39

JNJ Johnson & Johnson

Best for Income Investors
• Higher 5-Year Avg Yield: 2.77%
• Lower Payout Ratio: 59.52%
Best for Growth Investors
• Higher Revenue Growth: 9.90%
• Higher Return on Equity: 26.42%
• Higher Forward EPS: 12.71

Watch Out

JNJ's earnings declined 53% — declining profits may mean current valuation metrics (PE, payout ratio) are misleading.

Analyst Upside / Downside

ABT
+35.9%
JNJ
+9.8%

Based on analyst mean price targets. Estimates are not guaranteed and may not reflect future performance.

About These Companies

Abbott Laboratories (ABT)

Health Care · United States · NYQ

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, …

View ABT details →

Johnson & Johnson (JNJ)

Health Care · United States · NYQ

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in …

View JNJ details →

Frequently Asked Questions

Which has a better dividend yield, ABT or JNJ?
Abbott Laboratories currently has the higher dividend yield. Abbott Laboratories (ABT) yields 2.89% while Johnson & Johnson (JNJ) yields 2.29%. Past dividends do not guarantee future payments.
Which is more volatile, ABT or JNJ?
Abbott Laboratories is more volatile based on beta. Abbott Laboratories has a beta of 0.65 and Johnson & Johnson has a beta of 0.26. A beta above 1.0 means higher volatility than the overall market.
Which is cheaper by P/E ratio, ABT or JNJ?
Abbott Laboratories has the lower trailing P/E ratio. Abbott Laboratories trades at 23.7x earnings while Johnson & Johnson trades at 26.2x. A lower P/E may suggest better relative value, but could also reflect lower growth expectations.
Which has more analyst upside, ABT or JNJ?
Based on mean analyst price targets, Abbott Laboratories has more upside potential. Abbott Laboratories has +35.9% upside and Johnson & Johnson has +9.8% upside from current prices. Analyst estimates are not guaranteed.
Can I track both ABT and JNJ in one portfolio?
Yes. AllInvestView lets you add both Abbott Laboratories and Johnson & Johnson to the same portfolio and monitor price changes, dividends, total return, and allocation — completely free.

Track ABT and JNJ in Your Portfolio

Add both to AllInvestView and compare their real-time performance, dividends, and gain/loss side by side.

Start Free Portfolio

Related Comparisons

Health Care Peers

Stock Pages